{"id":"W2892927588","doi":"10.1634/theoncologist.2018-0290","title":"A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; Central China Normal University","keywords":"Bevacizumab; Glioblastoma; Medicine; Oncology; Randomized controlled trial; Internal medicine; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002469609,0.001730085,0.002416881,0.0005570209,0.0004402116,0.0009436085,0.0008855382,0.001550991,0.004230523],"category_scores_gemma":[0.002999844,0.0006755289,0.001803399,0.0004748937,0.001142035,0.0009003309,0.0004860865,0.002827122,0.0007358004],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009593415,"about_ca_system_score_gemma":0.001854028,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00121537,"about_ca_topic_score_gemma":0.003353168,"domain_scores_codex":[0.9988373,0.0007016158,0.00006710443,0.0002068409,0.0000758049,0.00011122],"domain_scores_gemma":[0.9982268,0.0004609786,0.0005226619,0.0001580948,0.0001214327,0.0005100726],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9645599,0.006313551,0.00119114,0.0005142506,0.001063416,0.00004513382,0.00006277132,0.0002922086,0.003400738,0.0001209768,0.0009247445,0.02151121],"study_design_scores_gemma":[0.9529296,0.04483603,0.0009722202,0.00001829253,0.0003705953,0.00003601519,0.000007722059,0.0002230974,0.0002035884,0.00006317114,0.0003327069,0.000007010266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984957,0.005185101,0.0009626296,0.0009830899,0.000520052,0.005211075,0.0008242138,0.000162029,0.001194858],"genre_scores_gemma":[0.9795997,0.002302467,0.003495449,0.001365356,0.0006800443,0.009615708,0.001217789,0.00003680322,0.001686756],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004230523,"threshold_uncertainty_score":0.01415253,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09663458954944744,"score_gpt":0.4254431738527606,"score_spread":0.3288085843033132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}